JCM
ITCI

JS Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

JS Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,300
Closed -$232K – 206
2020
Q4 		$232K Buy
+7,300
New +$192K 0.01% 123

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

JS Capital Management's ITCI Position: Q1 2021 in Review

JS Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2021, closing a stake of 7,300 shares — an estimated $232K sold.

JS Capital Management first reported a position in ITCI in Q4 2020 and held it in 1 quarter. The position peaked at $232K in Q4 2020. 170 funds tracked by Wall St. Rank hold ITCI as of Q1 2021.

  • JS Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2021 after selling out during the quarter.
  • JS Capital Management sold 7,300 Intra-Cellular Therapies Inc. shares in Q1 2021, an estimated $232K.
  • JS Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 1 quarter.
  • JS Capital Management's Intra-Cellular Therapies Inc. position peaked at $232K in Q4 2020.
  • 170 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2021.

Based on JS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.